Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin’s Lymphomas. ANRS 085 Rituximab
HIV infection is associated with a high incidence of AIDS-related lymphomas (ARL). Since the
use of highly active antiretroviral therapy (HAART), the incidence of AIDS-defining
illnesses has decreased, leading to a significant improvement in survival of HIV-infected
patients. The incidence of ARL has decreased in a lower degree and lymphoma remains the
major cause of death of HIV patients. Most treatment procedures disclose a relatively poor
outcome of patients with low response rates, high number of relapses and AIDS events. Since
the majority of HIV-associated NHL are CD20-positive the addition of rituximab to the
standard regimen - CHOP could improve the outcome of these patients
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the response rate of lymphoma treated
Francois Boue, MD
Principal Investigator
Service de Medecine Interne Hopital A Beclere Clamart France
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
ANRS 085 Rituximab
NCT00126243
January 1999
October 2003
Name | Location |
---|